Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PRTA -Prothena Corporation plc

Float Short %

10.07

Margin Of Safety %

Put/Call OI Ratio

1

EPS Next Q Diff

1.4

EPS Last/This Y

-2.32

EPS This/Next Y

3.48

Price

8.77

Target Price

26

Analyst Recom

2

Performance Q

33.89

Relative Volume

0.78

Beta

-0.06

Ticker: PRTA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PRTA6.680.950.3925241
2025-07-28PRTA6.880.950.0725398
2025-07-29PRTA6.930.940.2625531
2025-07-30PRTA6.860.941.1525623
2025-07-31PRTA6.880.941.2625742
2025-08-01PRTA6.80.952.5026988
2025-08-04PRTA6.920.960.0026997
2025-08-05PRTA7.010.940.3227161
2025-08-06PRTA7.910.880.5729407
2025-08-07PRTA7.730.784.2131049
2025-08-08PRTA7.70.8080.6131548
2025-08-11PRTA7.662.311.9658546
2025-08-12PRTA7.542.321.2959228
2025-08-13PRTA8.052.321.9360874
2025-08-14PRTA8.072.3225.5263120
2025-08-15PRTA8.262.340.8563657
2025-08-18PRTA8.530.902.7534386
2025-08-19PRTA8.520.961.1836202
2025-08-20PRTA8.520.964.9336378
2025-08-21PRTA8.551.000.7337296
2025-08-22PRTA8.771.001.8937584
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PRTA6.68-246.7- -4.54
2025-07-28PRTA6.84-246.7- -4.54
2025-07-29PRTA6.93-246.7- -4.54
2025-07-30PRTA6.88-246.7- -4.54
2025-07-31PRTA6.87-246.7- -4.54
2025-08-01PRTA6.81-246.7- -4.54
2025-08-04PRTA6.94-246.7- -4.54
2025-08-05PRTA7.03-246.7- -4.54
2025-08-06PRTA7.92-246.7- -4.54
2025-08-07PRTA7.72-246.7- -4.54
2025-08-08PRTA7.69-246.7- -4.55
2025-08-11PRTA7.6637.7- -4.55
2025-08-12PRTA7.5437.7- -4.55
2025-08-13PRTA8.0537.7- -4.55
2025-08-14PRTA8.0837.7- -4.55
2025-08-15PRTA8.2437.7- -4.55
2025-08-18PRTA8.5337.7- -4.55
2025-08-19PRTA8.5237.7- -4.55
2025-08-20PRTA8.5237.7- -4.55
2025-08-21PRTA8.5537.7- -4.55
2025-08-22PRTA8.7746.4- -4.59
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PRTA-34.54-29.1411.24
2025-07-28PRTA-34.54-28.9211.24
2025-07-29PRTA-34.54-28.9211.24
2025-07-30PRTA-34.54-28.9211.24
2025-07-31PRTA-34.54-28.9211.24
2025-08-01PRTA-34.54-28.9211.24
2025-08-04PRTA-34.54-29.1411.41
2025-08-05PRTA-33.33-29.1411.41
2025-08-06PRTA-33.33-29.1411.41
2025-08-07PRTA-33.32-29.1411.41
2025-08-08PRTA-33.32-29.1411.41
2025-08-11PRTA-33.32-29.1211.41
2025-08-12PRTA-33.32-29.1210.50
2025-08-13PRTA-33.32-29.1210.50
2025-08-14PRTA-33.32-29.1210.50
2025-08-15PRTA-33.32-29.1210.50
2025-08-18PRTA-33.32-24.6510.07
2025-08-19PRTA-36.94-24.6510.07
2025-08-20PRTA-36.94-24.6510.07
2025-08-21PRTA-36.94-24.6510.07
2025-08-22PRTA-36.94-24.6510.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.86

Avg. EPS Est. Current Quarter

-0.59

Avg. EPS Est. Next Quarter

-0.46

Insider Transactions

-36.94

Institutional Transactions

-24.65

Beta

-0.06

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

6

Fair Value

Quality Score

16

Growth Score

36

Sentiment Score

46

Actual DrawDown %

89

Max Drawdown 5-Year %

-94.2

Target Price

26

P/E

Forward P/E

PEG

P/S

45.66

P/B

1.46

P/Free Cash Flow

EPS

-5.63

Average EPS Est. Cur. Y​

-4.59

EPS Next Y. (Est.)

-1.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2929.3

Relative Volume

0.78

Return on Equity vs Sector %

-118.1

Return on Equity vs Industry %

-105.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

Prothena Corporation plc
Sector: Healthcare
Industry: Biotechnology
Employees: 163
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
stock quote shares PRTA -Prothena Corporation plc Stock Price stock today
news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRTA -Prothena Corporation plc yahoo finance google finance
stock history PRTA -Prothena Corporation plc invest stock market
stock prices PRTA premarket after hours
ticker PRTA fair value insiders trading